Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    ttp488

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (STEADFAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02080364
Recruitment Status : Terminated (Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.)
First Posted : March 6, 2014
Last Update Posted : May 17, 2019
Sponsor:
Information provided by (Responsible Party):
vTv Therapeutics

Brief Summary:
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: Azeliragon Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 880 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine
Actual Study Start Date : April 2015
Actual Primary Completion Date : June 1, 2018
Actual Study Completion Date : June 1, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Azeliragon 5mg
Azeliragon (TTP488) 5mg orally once daily for 18 months
Drug: Azeliragon
Azeliragon 5mg administered orally, once daily for 18 months
Other Name: TTP488

Placebo Comparator: Placebo
Placebo orally once daily for 18 months
Drug: Placebo
Placebo administered orally, once daily for 18 months




Primary Outcome Measures :
  1. Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) total score [ Time Frame: 18 months ]
  2. Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. Change from Baseline in Magnetic Resonance Imaging (MRI) brain volumetric measures [ Time Frame: 18 months ]
  2. Change from Baseline in Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Scan [ Time Frame: 18 months ]
  3. Change from Baseline in Neuropsychiatric Inventory (NPI) [ Time Frame: 18 months ]
  4. Change from Baseline in Mini-Mental State Examination (MMSE) [ Time Frame: 18 months ]
  5. Change from Baseline in Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL) [ Time Frame: 18 months ]
  6. Change from Baseline in Continuous Oral Word Association Task (COWAT) [ Time Frame: 18 month ]
  7. Change from Baseline in Category Fluency Test (CFT) [ Time Frame: 18 months ]
  8. Change from Baseline in Resource Utilization in Dementia (RUD) [ Time Frame: 18 months ]
  9. Change from Baseline in Dementia Quality of Life (DEMQOL) [ Time Frame: 18 months ]
  10. Change from Baseline in Plasma Amyloid Beta [ Time Frame: 18 months ]
  11. Proportion of Responders based on ADAS-cog [ Time Frame: 18 months ]
  12. Proportion of Responders based on CDR-SB [ Time Frame: 18 months ]
  13. Adverse Events [ Time Frame: 21 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease
  • Mini Mental State Examination (MMSE) score of 21-26, inclusive
  • Clinical Dementia Rating global score of 0.5 or 1
  • Rosen-Modified Hachinski Ischemia Score less than or equal to 4
  • Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD
  • Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 3 months prior to randomization
  • Caregiver willing to participate and be able to attend clinic visits with patient
  • Ability to ingest oral medications

Exclusion Criteria:

  • Significant neurological or psychiatric disease other than Alzheimer's disease
  • Participants with evidence or history of severe drug allergies (resulting in dyspnea or severe rash).
  • Any contraindications to MRI (e.g., clinically significant claustrophobia, non-removable ferromagnetic implants). Patients with contraindications to MRI may undergo computed tomography (CT) on approval by sponsor.
  • Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG dose) in the cohort undergoing a PET scan.
  • Previous exposure to investigational or non-investigational therapies for Alzheimer's disease within 6 months of screening
  • History of cancer within the last 5 years except adequately treated cervical carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not requiring treatment
  • Women of childbearing potential
  • Uncontrolled blood pressure and/or blood pressure above 160/100
  • Prescription medical food intended for dietary management of the metabolic processes associated with Alzheimer's disease.
  • Diagnosis or history of cerebrovascular stroke, severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage.
  • Patients with unstable, uncontrolled diabetes (HbA1c > 7.7%) and those requiring insulin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02080364


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
Phoenix, Arizona, United States, 85004
Phoenix, Arizona, United States, 85013
Phoenix, Arizona, United States, 85018
Tucson, Arizona, United States, 85724
Tucson, Arizona, United States, 85741
United States, California
Bellflower, California, United States, 90706
Costa Mesa, California, United States, 92626
Fullerton, California, United States, 92835
Glendale, California, United States, 91206
Imperial, California, United States, 92251
Irvine, California, United States, 92614
Laguna Hills, California, United States, 92653
Long Beach, California, United States, 90806
Long Beach, California, United States, 90807
Orange, California, United States, 92868
Riverside, California, United States, 92506
San Bernardino, California, United States, 92408
San Francisco, California, United States, 94114
Santa Ana, California, United States, 92705
United States, Florida
Atlantis, Florida, United States, 33462
Brooksville, Florida, United States, 34601
Delray Beach, Florida, United States, 33445
Hallandale Beach, Florida, United States, 33009
Hialeah, Florida, United States, 33016
Jacksonville, Florida, United States, 32216
Lake Worth, Florida, United States, 33449
Leesburg, Florida, United States, 34748
Miami Beach, Florida, United States, 33140
Miami Lakes, Florida, United States, 33014
Miami Lakes, Florida, United States, 33016
Miami, Florida, United States, 33122
Miami, Florida, United States, 33137
Orlando, Florida, United States, 32806
Pensacola, Florida, United States, 32503
Sarasota, Florida, United States, 34243
Sunrise, Florida, United States, 33351
United States, Georgia
Atlanta, Georgia, United States, 30331
Columbus, Georgia, United States, 31909
United States, Illinois
Chicago, Illinois, United States, 60640
United States, Kansas
Fairway, Kansas, United States, 66205
Prairie Village, Kansas, United States, 66201
United States, Kentucky
Lexington, Kentucky, United States, 40504
United States, Maryland
Baltimore, Maryland, United States, 21208
United States, Massachusetts
Newton, Massachusetts, United States, 02459
Plymouth, Massachusetts, United States, 02360
Quincy, Massachusetts, United States, 01269
United States, Mississippi
Hattiesburg, Mississippi, United States, 39401
United States, Missouri
Creve Coeur, Missouri, United States, 63141
United States, New Jersey
Princeton, New Jersey, United States, 08540
United States, New Mexico
Albuquerque, New Mexico, United States, 87109
United States, New York
Albany, New York, United States, 12208
Lake Success, New York, United States, 11042
New York, New York, United States, 10032
Staten Island, New York, United States, 10312
United States, North Carolina
Charlotte, North Carolina, United States, 28270
Raleigh, North Carolina, United States, 27607
Wilmington, North Carolina, United States, 28401
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Canton, Ohio, United States, 44718
Shaker Heights, Ohio, United States, 44122
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73103
Oklahoma City, Oklahoma, United States, 73118
United States, Oregon
Portland, Oregon, United States, 97210
Portland, Oregon, United States, 97225
United States, Pennsylvania
Media, Pennsylvania, United States, 19063
Norristown, Pennsylvania, United States, 19403
Plains, Pennsylvania, United States, 18705
United States, Rhode Island
East Providence, Rhode Island, United States, 02914
East Providence, Rhode Island, United States, 02916
United States, South Carolina
Charleston, South Carolina, United States, 24901
Mount Pleasant, South Carolina, United States, 29464
United States, Tennessee
Cordova, Tennessee, United States, 38018
Nashville, Tennessee, United States, 37203
United States, Texas
Dallas, Texas, United States, 75231
San Antonio, Texas, United States, 78229
San Antonio, Texas, United States, 78232
Wichita Falls, Texas, United States, 76309
United States, Utah
Murray, Utah, United States, 84123
United States, Washington
Kirkland, Washington, United States, 98201
Richland, Washington, United States, 99352
Australia, Queensland
Southport, Queensland, Australia, 4222
Australia, Victoria
Caulfield, Victoria, Australia, 3162
Geelong, Victoria, Australia, 3220
Heidelberg West, Victoria, Australia, 3081
Australia, Western Australia
Nedlands, Western Australia, Australia, 6009
West Perth, Western Australia, Australia, 6005
Canada, Alberta
Calgary, Alberta, Canada, T2N 4Z6
Medicine Hat, Alberta, Canada, T1B 4E7
Canada, Nova Scotia
Kentville, Nova Scotia, Canada, B4N4K9
Canada, Ontario
Chatham, Ontario, Canada, N7L 1C1
London, Ontario, Canada, N6C 5J1
Toronto, Ontario, Canada, M3B 257
Canada, Quebec
Gatineau, Quebec, Canada, J8T 8J1
Greenfield Park, Quebec, Canada, J4V2J2
Ireland
Cork, Ireland
Dublin 8, Ireland
Galway, Ireland
New Zealand
Christchurch, Canterbury, New Zealand, 8011
Christchurch, Canterbury, New Zealand, 8022
South Africa
Cape Town, South Africa, 7405
Cape Town, South Africa, 7530
Johannesburg, South Africa, 2196
St. George, South Africa, 6529
United Kingdom
Glasgow, United Kingdom, G20 OAXA
London, United Kingdom, W1G 9RU
London, United Kingdom, WC1X 8QD
Manchester, United Kingdom, M8 5RB
Northampton, United Kingdom, NN5 6UD
Oxford, United Kingdom, OX3 7JX
Penarth, United Kingdom, CF64 2XX
Preston, United Kingdom, PR2 9HT
Sheffield, United Kingdom, S5 7JT
Southhampton, United Kingdom, SO30 3JB
Swindon, United Kingdom, SN3 6BW
Warrington, United Kingdom, WA2 8WA
Sponsors and Collaborators
vTv Therapeutics
Investigators
Layout table for investigator information
Study Director: Aaron H Burstein, PharmD vTv Therapeutics

Additional Information:
Layout table for additonal information
Responsible Party: vTv Therapeutics
ClinicalTrials.gov Identifier: NCT02080364     History of Changes
Other Study ID Numbers: TTP488-301
First Posted: March 6, 2014    Key Record Dates
Last Update Posted: May 17, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by vTv Therapeutics:
Alzheimer's disease
RAGE
ADAS-cog
CDR-sb

Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs